

## Supporting Information

### Self-assembly of Keggin-type U(VI)-containing tungstophosphates with a sandwich structure: an efficient catalyst for the synthesis of sulfonyl pyrazoles

Guo-Ping Yang,<sup>a</sup> Xing-Lei Zhang,<sup>a</sup> Yu-Feng Liu,<sup>a</sup> Dong-Di Zhang,<sup>\*b</sup> Ke Li<sup>\*a</sup> and Chang-Wen Hu<sup>\*c</sup>

<sup>a</sup> Jiangxi Province Key Laboratory of Synthetic Chemistry, Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, East China University of Technology, Nanchang, Jiangxi 330013, P. R. China.

<sup>b</sup> Henan Key Laboratory of Polyoxometalate Chemistry, College of Chemistry and Chemical Engineering, Henan University, Kaifeng, Henan 475004, P. R. China.

<sup>c</sup> Key Laboratory of Cluster Science of Ministry of Education, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, P. R. China.

\* E-mails: like90@foxmail.com (K. Li), ddzhang@henu.edu.cn (D.-D. Zhang), cwhu@bit.edu.cn (C.-W. Hu)

### Table of Contents

1. General Information.....	2
2. Experiment.....	3
3. Characterization of <b>1</b> and <b>2</b> .....	4
4. Characterization of Products.....	11
5. NMR Spectra.....	14
6. Notes and References.....	25

## 1. General Information

### **Materials and Methods**

$\text{Na}_9[\text{A-PW}_9\text{O}_{34}] \cdot 7\text{H}_2\text{O}$  was prepared according to the reported method.<sup>[1]</sup> Other reagents were of reagent grade quality, obtained from commercial sources, and used without further purification. *CAUTION! Uranium compounds are radioactive and can cause cancers and skin and eye irritation.*

The FT-IR spectra were obtained by using a Fourier transform infrared (FT-IR) (4000-500  $\text{cm}^{-1}$ ) spectrometer (Thermo Nicolet iS5) at 0.5  $\text{cm}^{-1}$  resolution and 16 scans. Powder X-ray diffraction (PXRD) was performed on a Bruker D8 Advance diffractometer with Cu  $\text{K}\alpha$  radiation ( $\lambda = 1.5406 \text{ \AA}$ ) at room temperature.

The single crystal X-ray diffraction data was collected on Bruker D8 Smart Apex II diffractometer with graphite monochromated Mo  $\text{K}\alpha$  radiation ( $\lambda = 0.71073 \text{ \AA}$ ). Intensities were collected by  $\omega$ -scan and reduced on APEX 3 (Bruker AXS Inc., 2016) and a multi-scan absorption correction was applied.<sup>[2]</sup> Hydrogen atoms of partial water molecular were added in calculated positions. The structures were solved and refined on Olex2 using SHELXTL package.<sup>[3]</sup> Parameters of the crystal data collection and refinement are given in Table S1. The CSD numbers are 2067677 and 2067678.

### **Methods for the Characterization of Products**

The starting materials were commercially available and were used without further purification. The products were isolated by column chromatography on silica gel (200-300 mesh) using petroleum ether (60-90 °C) and ethyl acetate. All compounds were characterized by  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectrometry, which were consistent with those reported in related literatures. NMR spectra were determined on Bruker Ascend 500 in  $\text{CDCl}_3$ .  $^1\text{H}$  NMR chemical shifts were referenced to residual solvent as determined relative to  $\text{CDCl}_3$  (7.26 ppm). The  $^{13}\text{C}$  NMR chemical shifts were reported in ppm relative to the carbon resonance of  $\text{CDCl}_3$  (central peak is 77.0 ppm).  $^1\text{H}$  NMR peaks were labeled as singlet (s), doublet (d), triplet (t), and multiplet (m). The coupling constants,  $J$ , are reported in Hertz (Hz). GC analyses were performed on Agilent 7890B equipped with a capillary column (HP-5, 30 m  $\times$  0.25  $\mu\text{m}$ ) using a flame ionization detector.

## 2. Experiment

### ***Synthesis of $\text{Na}_{11}\text{H}(\text{H}_2\text{O})_{31}[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2 \cdot 7\text{H}_2\text{O}$ (**1**)***

$\text{UO}_2(\text{OAc})_2 \cdot 2\text{H}_2\text{O}$  (0.2 mmol, 0.0848 g) was dissolved in 20 mL 0.25 M NaCl solution.  $\text{Na}_9[\text{A-PW}_9\text{O}_{34}] \cdot 7\text{H}_2\text{O}$  (0.2 mmol, 0.5125 g) was then added into the solution. The mixture was stirred until  $\text{Na}_9[\text{A-PW}_9\text{O}_{34}] \cdot 7\text{H}_2\text{O}$  dissolved completely and then was adjusted to pH = 5.1 using 1 M HCl. The cloudy solution was stirred at 85 °C for 30 min. After cooling to room temperature, 5 g NaCl was added into the mixture and stirred for 5 min. The mixture was filtered and the filtrate was kept stand still at room temperature. Crystals will come out after one night. Yellow irregular block crystals of **1** were collected after 7 days. IR ( $\text{cm}^{-1}$ ; s, strong; m, medium; w, weak): 3394 (s), 1635 (m), 1061 (s), 1009 (m), 947 (s), 912 (s), 858 (s), 839 (s), 781 (vs), 720 (vs), 665 (vs), 512 (w), 501 (w).

### ***Synthesis of $\text{Na}_{12}(\text{H}_2\text{O})_{29}[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2 \cdot 7\text{H}_2\text{O}$ (**2**)***

The synthesis procedure of **2** is similar to **1** except the pH was adjusted to 6.9. Yellow parallelogram plate crystals of **2** were collected after 7 days. IR ( $\text{cm}^{-1}$ ; s, strong; m, medium; w, weak): 3389 (s), 1635 (m), 1061 (s), 1009 (m), 947 (m), 913 (s), 860 (s), 840 (s), 780 (vs), 719 (vs), 665 (vs), 570 (s), 506 (w).

### ***Typical procedure of the compound 1 catalyzed condensation reaction***

To a 4 mL reaction vial, benzenesulfonyl hydrazide (1 mmol), 3-methyl-2,4-pentanedione (1 mmol), compound **1** (1 mol%) and EtOH (0.1 mL) were added. Then the reaction was carried out in screw cap vials with a Teflon seal at 80 °C for the desired time. After reaction, the mixture was purified by column chromatography (petroleum ether/EtOAc) to afford the desired products. However, some products could also be obtained by recrystallization.

### 3. Characterization of 1 and 2.




Fig. S1 Polyhedral representation view of the polyanion in 1.




Fig. S2 Coordination mode of U1 in 1.







Fig. S3 View of the {NaUO<sub>2</sub>}<sub>2</sub> in 1.




**Fig. S4** Coordination modes of Na2, Na3, Na4 and Na5 in **1**.




**Fig. S5** Coordination modes of Na5, Na6 and Na7 in **1**.




**Fig. S6** One  $[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2^{12-}$  polyanion (orange) is surrounded by eight adjacent polyanions (aqua) in **1**.




**Fig. S7** Keggin-sandwich structure of **2**; (a) ball and stick representation view; (b) polyhedral representation view of the polyanion.




**Fig. S8** Coordination mode of U1 in **2**.




**Fig. S9** Top view (a) and side view (b) of the  $\{\text{NaUO}_2\}_2$  cluster in **2**.




**Fig. S10** One  $[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2^{12-}$  polyanion (orange) is surrounded by eight adjacent polyanions (aqua) in **2**.



**Fig. S11** All the Na(I) ions coordinated with one  $[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2^{12-}$  polyanion in (a) **1**, (b) **2** and (c) the reported structure; the structural comparison between (d) **1**, (e) **2** and (f) the reported structure.



**Fig. S12** One  $[\text{Na}(\text{UO}_2)(\text{PW}_9\text{O}_{34})]_2^{12-}$  polyanion (orange) is surrounded by eight adjacent polyanions (aqua) in the reported structure.



**Fig. S13** FT-IR spectrum of 1.






Fig. S14 FT-IR spectrum of 2.





Fig. S15 PXRD pattern of 1.

The PXRD patterns of **1** before and after the catalytic reaction match well with the simulated PXRD, indicating the stability of **1** in the reaction.




**Fig. S16** PXRD pattern of **2**.

**Table S1** Crystallographic data and structure refinement for **1**, **2** and the reported structure.

	<b>1</b>	<b>2</b>	the reported structure
CSD No.	2067677	2067678	-
Empirical formula	Na <sub>13</sub> O <sub>110</sub> P <sub>2</sub> U <sub>2</sub> W <sub>18</sub> H <sub>77</sub>	Na <sub>14</sub> O <sub>108</sub> P <sub>2</sub> U <sub>2</sub> W <sub>18</sub> H <sub>72</sub>	Na <sub>14</sub> O <sub>110</sub> U <sub>2</sub> P <sub>2</sub> W <sub>18</sub> H <sub>76</sub>
Fw	5983.78	5959.73	6005.77
T/K	150	149.97	173(2)
Crystal system	monoclinic	monoclinic	monoclinic
Space group	<i>P</i> 2 <sub>1</sub> / <i>c</i>	<i>P</i> 2 <sub>1</sub> / <i>n</i>	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<i>a</i> /Å	16.7726(3)	16.7416(4)	16.6797(8)
<i>b</i> /Å	14.6382(3)	14.6282(3)	14.6412(7)
<i>c</i> /Å	21.2673(4)	21.2633(7)	21.2925(10)
$\alpha$ (°)	90	90	90
$\beta$ (°)	112.7500(10)	112.6870(10)	112.2600(10)
$\gamma$ (°)	90	90	90
<i>V</i> /Å <sup>3</sup>	4815.33(16)	4804.5(2)	4812.3(4)
<i>F</i> (000)	5292.0	5272.0	5312.0
<i>Z</i>	2	2	2
$\rho_{\text{calcd}}$ (g·cm <sup>-3</sup> )	4.127	4.127	4.145
$\mu$ (mm <sup>-1</sup> )	24.977	25.035	24.997
Reflections collected	46446	39677	52355
Unique reflections	11971 ( <i>R</i> <sub>int</sub> = 0.0430)	11886 ( <i>R</i> <sub>int</sub> = 0.0415)	11682 ( <i>R</i> <sub>int</sub> = 0.1068)
Parameter	676	676	572
GOOF on <i>F</i> <sup>2</sup>	1.062	1.071	1.156
<i>R</i> <sub>1</sub> [ <i>I</i> ≥ 2σ( <i>I</i> )]	0.0273	0.0278	0.0549
<i>wR</i> <sub>2</sub> (all data)	0.0540	0.0568	0.1548
Largest diff. peak/hole/e Å <sup>-3</sup>	1.77/-1.44	1.33/-1.84	3.72/-4.22

#### 4. Characterization of Products<sup>[4]</sup>




##### 3,4,5-trimethyl-1-(phenylsulfonyl)-1H-pyrazole (3a)

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.90 (d, *J* = 7.4 Hz, 2H), 7.58 (t, *J* = 7.5 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 2H), 2.39 (s, 3H), 2.14 (s, 3H), 1.82 (s, 3H);

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ (ppm) 154.01, 139.75, 138.45, 133.84, 129.25, 127.42, 117.45, 12.48, 11.38, 8.06.

---




##### 3,5-dimethyl-1-(phenylsulfonyl)-1H-pyrazole (3b)

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.97-7.90 (m, 2H), 7.49-7.61 (m, 3H), 5.92 (s, 1H), 2.48 (s, 3H), 2.18 (s, 3H);

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ (ppm) 153.60, 144.20, 138.08, 134.10, 129.31, 127.32, 110.98, 13.77, 13.03.

---




##### 4-chloro-3,5-dimethyl-1-(phenylsulfonyl)-1H-pyrazole (3c)

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.96 (d, *J* = 7.4 Hz, 2H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.54 (t, *J* = 7.8 Hz, 2H), 2.50 (s, 3H), 2.22 (s, 3H);

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ (ppm) 151.15, 139.43, 137.61, 134.48, 129.49, 127.67, 113.94, 11.90, 11.28.

---




##### 3,4,5-trimethyl-1-tosyl-1H-pyrazole (3d)

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.81 (d, *J* = 8.3 Hz, 2H), 7.29 (d, *J* = 8.1 Hz, 2H), 2.40 (s, 6H), 2.15 (s, 3H), 1.83 (s, 3H);

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>): δ (ppm) 153.76, 144.95, 139.61, 135.50, 129.87, 127.46, 117.29, 21.68, 12.47, 11.36, 8.05.

---




**3,5-dimethyl-1-tosyl-1H-pyrazole (3e)**

$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.82 (d,  $J = 8.4$  Hz, 2H), 7.29 (d,  $J = 7.9$  Hz, 2H), 5.91 (s, 1H), 2.48 (s, 3H), 2.38 (s, 3H), 2.18 (s, 3H);

$^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 153.40, 145.25, 144.04, 135.20, 129.91, 127.43, 110.83, 21.59, 13.80, 13.06.

---




**4-chloro-3,5-dimethyl-1-tosyl-1H-pyrazole (3f)**

$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.84 (d,  $J = 8.3$  Hz, 2H), 7.33 (d,  $J = 8.2$  Hz, 2H), 2.49 (s, 3H), 2.42 (s, 3H), 2.21 (s, 3H);

$^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 150.93, 145.74, 139.30, 134.68, 130.10, 127.75, 113.78, 21.74, 11.91, 11.27.

---




**1-(4-chlorophenyl)sulfonyl-3,5-dimethyl-1H-pyrazole (3g)**

$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.90 (d,  $J = 8.4$  Hz, 2H), 7.49 (d,  $J = 7.2$  Hz, 2H), 5.94 (s, 1H), 2.50 (s, 3H), 2.20 (s, 3H);

$^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 154.04, 144.36, 140.70, 136.59, 129.64, 129.00, 111.15, 13.84, 13.13.


---



**1-(3-chlorophenyl)sulfonyl-3,5-dimethyl-1H-pyrazole (3h)**

$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 7.94 (s, 1H), 7.84 (s, 1H), 7.47-7.59 (m, 2H), 5.97 (s, 1H), 2.51 (s, 3H), 2.21 (s, 3H);

$^{13}\text{C NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 154.16, 144.44, 139.67, 135.33, 134.20, 130.72, 127.40, 125.61, 111.27, 13.82, 13.11.




**1-((2-chlorophenyl)sulfonyl)-3,5-dimethyl-1H-pyrazole (3i)**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.12 (d, *J* = 8.3 Hz, 1H), 7.54 (t, *J* = 7.7 Hz, 1H), 7.45 (d, *J* = 7.7 Hz, 2H), 5.95 (s, 1H), 2.57 (s, 3H), 2.14 (s, 3H);

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ (ppm) 153.60, 146.08, 135.99, 135.19, 132.57, 132.04, 131.67, 127.36, 109.85, 13.83, 13.51.

---




**1-((4-methoxyphenyl)sulfonyl)-3,5-dimethyl-1H-pyrazole (3j)**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ (ppm) 7.88 (d, *J* = 9.0 Hz, 2H), 6.96 (d, *J* = 9.0 Hz, 2H), 5.90 (s, 1H), 3.84 (s, 3H), 2.48 (s, 3H), 2.19 (s, 3H);

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ (ppm) 163.95, 153.24, 143.89, 129.78, 129.51, 114.48, 110.70, 55.72, 13.81, 13.12.

---




**3,5-dimethyl-1-((4-nitrophenyl)sulfonyl)-1H-pyrazole (3k)**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.37 (t, *J* = 8.0 Hz, 2H), 8.16 (t, *J* = 7.9 Hz, 2H), 5.97 (d, *J* = 7.2 Hz, 1H), 2.52 (d, *J* = 7.3 Hz, 3H), 2.20 (d, *J* = 7.5 Hz, 3H);

**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ (ppm) 154.93, 150.73, 144.85, 143.52, 129.06, 124.56, 111.64, 13.89, 13.20.

---





**3,5-dimethyl-1-(naphthalen-2-ylsulfonyl)-1H-pyrazole (3l)**

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ (ppm) 8.56 (s, 1H), 7.93-7.82 (m, 4H), 7.59 (dt, *J* = 15.0, 6.9 Hz, 2H), 5.89 (s, 1H), 2.54 (s, 3H), 2.18 (s, 3H);



**<sup>13</sup>C NMR** (126 MHz, CDCl<sub>3</sub>): δ (ppm) 153.65, 144.25, 135.26, 135.03, 131.84, 129.72, 129.59, 129.47, 129.32, 127.95, 127.84, 122.04, 110.96, 13.88, 13.23.



---



## 5. NMR Spectra













































## 6. Notes and References

- [1] A. P. Ginsberg, *Inorg. Synth.* **1990**, 27, 100.
- [2] Bruker, *APEX3*, *SAINT* and *SADABS*, Bruker AXS Inc., Madison, Wisconsin, USA, **2016**.
- [3] (a) O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J. Appl. Cryst.* **2009**, 42, 339; (b) G. M. Sheldrick, *Acta Cryst.* **2015**, A71, 3; (c) G. M. Sheldrick, *Acta Cryst.* **2015**, C71, 3.
- [4] (a) W. Xiong, J. X. Chen, M. C. Liu, J. C. Ding, H. Y. Wu, W. K. Su, *J. Brazil. Chem. Soc.* **2009**, 20, 367; (b) G. P. Yang, S. X. Shang, B. Yu, C. W. Hu, *Inorg. Chem. Front.* **2018**, 5, 2472; (c) G. S. Kumar, W. Kaminsky, K. J. R. Prasad, *Synthetic Commun.* **2015**, 45, 1751; (d) B. R. Vaddula, R. S. Varma, J. Leazer, *Tetrahedron Lett.* **2013**, 54, 1538.